Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma (NCT04970251) | Clinical Trial Compass
CompletedNot Applicable
Aflibercept as Adjunctive Treatment for Filtration Surgery in Neovascular Glaucoma
Thailand5 participantsStarted 2018-11-01
Plain-language summary
Purpose: To investigate intravitreal aflibercept (IVA) injection as an adjunctive treatment to trabeculectomy with mitomycin C (TMC) and panretinal photocoagulation (PRP) for neovascular glaucoma (NVG).
Setting: Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand Study design: Prospective interventional case series Methods: PRP and IVA (2 mg/0.05 ml) injection were given, and TMC was performed within 2 weeks after IVA. Additional PRP, laser suture lysis, subconjunctival 5-fluorouracil injection, and bleb needling were performed after TMC if indicated. Best-collected visual acuity (BCVA), intraocular pressure (IOP), surgical complications, and number of anti-glaucoma medications were collected.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Consecutive patients with neovascular glaucoma who presented at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand during November 2018 to October 2019.
* Aged more than 18 year-old
Exclusion Criteria:
* Patients who received any anti-vascular endothelial growth factor treatment before participation
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Since this trial has already been completed, has my doctor seen or can they access any published results showing whether aflibercept injections alongside filtration surgery actually helped lower intraocular pressure in neovascular glaucoma patients?
2Neovascular glaucoma is a serious condition — can my doctor explain whether the combination of aflibercept and filtration surgery used in this trial is something they would now consider for my case, or whether standard filtration surgery alone might still be the better first step for me?
3This trial was listed as 'Phase NA,' which can mean it was more of an observational or pilot study — does my doctor know how many patients were involved and whether the findings are strong enough to influence my treatment plan?
4Since one of the key targets in this trial was VEGF overexpression, can my doctor explain whether my specific type of neovascular glaucoma involves the kind of abnormal blood vessel growth that an anti-VEGF drug like aflibercept is designed to address?
5Given that intraocular pressure was measured at multiple time points in this trial, can my doctor tell me what kind of pressure control was achieved and how that compares to what I might realistically expect from my current treatment options?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.